A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and
pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or
platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending
intravenous doses of DMOT4039A.